Molbio Diagnosti Q1 FY27 Earnings Call — Analysis (NSE: MOLBIO)

Molbio debuted as a listed entity delivering Q1 FY27 revenue of ₹408 Cr with a 25% EBITDA margin, guiding for ~25% revenue growth and 24-25% EBITDA margins in FY27.

12 Sept 2026 · Analysis by Alpha Inflection

Result quality: strong — Loss reversed. Management sentiment: optimistic.

The take

Q1FY27 Consolidated Revenue from Operations ₹408 Cr . New guidance — FY27 molbio diagnostics consolidated… roughly about 25% . New story: Razor-and-Blade Consumable Monetization .

Results

Revenue ₹408 Cr; EBITDA ₹104 Cr (25.5% margin); PAT ₹52.7 Cr (12.9% margin); device sales of 164 units and test kit volume of 62.4 lakh units.

Financial highlights

Guidance

Management guided for FY27 revenue growth of roughly 25% with EBITDA margins of 24% to 25%.

What management committed to

• From a guidance perspective, we are looking to grow this year in terms of our top line at roughly about 25% — roughly about 25%, FY27
• We're looking to deliver an EBITDA of about 24% to 25% — 24% to 25%, FY27
• In terms of our device, we see historically, they've always ranged between the 2,200 to 2,600 kind of a level, which is what we also expect for the current year — 2,200 to 2,600, FY27
• R&D, we generally spend 5% to 6% of our revenue on R&D, and we'll continue to do the same — 5% to 6%, FY27
• For the full year, we expect that while Prognosys would deliver similar margins as full year last year, closer to about 19% EBITDA, OptraScan would not be profitable for FY27 — closer to about 19% EBITDA, FY27
• Of the INR200 crores that we've raised, about INR72 crores will go into automation... and about ₹105-odd crores would be used to build our own integrated R&D center in Bangalore — INR72 crores / ₹105-odd crores
• Right now, we have a two-year rate contract [with Government of India for TB]. This happened only last month. So, this contract is valid for two years now. — two years, FY29

Key themes

Point-of-care expansion and multi-disease rollout

How the narrative shifted

• Razor-and-Blade Consumable Monetization: Installed base of 12,500+ proprietary closed-loop Truenat devices drives a recurring 75% test kit revenue contribution with 60-63% gross margins.
• Public TB Expansion & Penetration: Significant headroom remains in India (reached only 8k-9k of 25k-30k TB diagnostic centers) and LMIC export markets to replace traditional smear microscopy with point-of-care molecular testing.
• Menu Expansion Beyond TB: Leveraging existing device hardware to scale new high-volume assays such as HPV, CT/NG, and hepatitis in domestic and international markets.
• Expansion into Regulated Export Markets: Achieving stringent regulatory milestones like EU IVDR and US FDA clearance allows entry into high-value developed markets across diagnostics and digital pathology.
• Lumpy Procurement Dynamics: Public health procurement cycles create non-linear quarterly revenue and volume swings, requiring annual rather than sequential performance evaluation.

Operational commentary

• Installed base reached 12,500+ Truenat machines across 90+ countries with >40 million cumulative tests conducted.
• Truenat consumable sales represent recurring revenue model contributing ~75% of total revenues.
• Secured a fresh 2-year TB rate contract with the Government of India in August 2026.
• Capacity utilization stands at 58% for test kits and 42% for devices, with existing footprint capable of supporting 2x top-line growth with minimal capex.
• Subsidiary OptraScan received US FDA clearance in July 2026 for its end-to-end digital pathology solution (hardware, cloud software, and AI).
• Received EU IVDR certification for the Truenat CT/NG (sexually transmitted infection) assay, opening European market entry.
• Validation conducted by AIIMS/WHO/Gates Foundation recommended Truenat HPV test for roll-out under India's national cervical screening program.

Analyst Q&A

• Q. Expected first-year volumes and roll-out timeline for the Truenat HPV test in India

  Management stated it is hard to comment at this stage and deferred specific guidance until the next quarter earnings call as deployment algorithms are finalized.

• Q. Commercial traction, target customer adoption, and revenue timelines for OptraScan post-FDA clearance

  Discussions have started with large US laboratory and hospital chains; FY27 will see muted financial impact with continued losses, but meaningful revenue and profit contribution is expected starting FY28 and FY29.

• Q. Truenat device life cycle and consumable lock-in

  Truenat devices installed since 2017-18 are still operational without requiring replacement cycles yet; the system is fully closed-loop and runs exclusively on proprietary reagents.

• Q. Rationale for lower quarterly device volume sales and pricing realizations

  Public health procurement is lumpy and non-linear; full-year device run-rate remains 2,200-2,600 units, while realization swings reflect bay mix (Uno/Duo/Quattro) and FX rather than gross margin degradation.

View source

Research and educational content only. Not investment advice.